

### Overview of CML related sessions at 23<sup>rd</sup> EHA Meeting in Stockholm

Time slots	Sessions	Location
<b>June 14th (Thursday)</b>		
8.00 – 10.00	<p><b>Satellite Symposium:</b> Targeting the individual: Personalized treatment in CML (Supported by Pfizer Oncology)</p> <p>Chair:</p> <ul style="list-style-type: none"> <li>• Prof. R Clark (Royal Liverpool University Hospital, UK)</li> </ul> <p>Program:</p> <ul style="list-style-type: none"> <li>• Introduction (R Clark)</li> <li>• A new option in the treatment of first-line CML (M Deininger)</li> <li>• A wealth of choices in first-line CML: how to choose the right TKI in first line (R Clark)</li> <li>• Treatment options in second-line and beyond: A case-based discussion (D Wolf)</li> <li>• Chronic treatment vs. cure: future challenges in CML treatment (H Hjort-Hansen)</li> <li>• Q&amp;A (R. Clark)</li> </ul>	Room A2
10.45 – 12.45	<p><b>Satellite Symposium:</b> Recent advances in CML and MPN's (Supported by Novartis Oncology)</p> <p>Chairs:</p> <ul style="list-style-type: none"> <li>• Prof. A Hochhaus (University Hospital Jena, Germany)</li> <li>• Dr J Samuelsson (Stockholm South Hospital, Sweden)</li> </ul> <p>Program:</p> <ul style="list-style-type: none"> <li>• Welcome (S. Samuelsson)</li> </ul>	Room A1

Time slots	Sessions	Location
	<ul style="list-style-type: none"> <li>• Current treatment landscape in CML (TP Hughes)</li> <li>• Current treatment landscape in classical MPN (RA Mesa)</li> <li>• Challenges and future perspectives in CML (JE Cortes)</li> <li>• Challenges and future perspectives in classical MPN's (AM Vannucchi)</li> <li>• Summary and Q&amp;A (A Hochhaus)</li> </ul>	
10.45 – 12.45	<p><b>Satellite Symposium:</b> Immuno-oncology in haematologic malignancies: The evolving biomarker story (Supported by Bristol Myers Squibb)</p> <p>Chair: Dr O Landgren (Memorial Sloan Kettering Cancer Center, New York, USA)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• Insights and current perspectives: An Introduction to I-O advances and biomarker research (O. Landgren)</li> <li>• Gaining an understanding of the relationship between the tumor and the tumor microenvironment (B Paiva)</li> <li>• The individualized approach: Personalizing medicine through biomarkers (A Diepstra)</li> <li>• Evolving bench to bedside and back: Designing biology-driven studies (N Daver)</li> </ul>	Room A2
<b>June 15th (Friday)</b>		
14.30 – 15.30	<p><b>Meet-the-expert:</b> Treatment options in resistant CML patients</p> <p>Speaker: Prof. J Apperley</p>	Room A12
<b>June 16<sup>th</sup> (Saturday)</b>		
8.00 – 9.30	<p><b>Patient Advocacy Session 1:</b> PRO measurement and patient-relevant endpoints</p> <p>Program: tbd</p>	Room K21

Time slots	Sessions	Location
9.45 – 10.45	<b>Scientific Working Group (SWG):</b> Chronic myeloid leukemia – ELN-EHA SWG session on CML 2018 Chair: <ul style="list-style-type: none"> <li>Prof. R Hehlmann (ELN Foundation, Weinheim, Germany)</li> </ul> Program: <ul style="list-style-type: none"> <li>The relevance of cytogenetics in the course of CML (C Haferlach)</li> <li>Does IFN improve outcome of CML in the imatinib era? (FE Nicolini)</li> <li>Wordwide standardization of BCR-ABL monitoring (N Cross)</li> <li>End results of the EUTOS-registry project (M Baccarani)</li> </ul>	Room A8
11.30 – 12.45	<b>Patient Advocacy Session 2:</b> Quality of life for elderly, delivery of treatments in home settings, and pre-rehabilitation Program: tbd	Room K21
14.45 – 15.45	<b>Advocacy Session:</b> EU projects in hematology: HARMONY update Program: tbd	Room K2
16.00 – 17.15	<b>EHA Advocacy Session:</b> The real-world value of new generation treatments Program: tbd	Room K21
17.30 – 19.00	<b>Update in Hematology:</b> Biosimilars in Hematology – Plotting the course to long-term sustainability (Supported by Sandoz) Chair: <ul style="list-style-type: none"> <li>Dr PC Cornes (Comparative Outcomes Group, Bristol, UK)</li> </ul>	Room A7

Time slots	Sessions	Location
	<p>Program:</p> <ul style="list-style-type: none"> <li>• Introduction and welcome (PC Cornes)</li> <li>• A patient's journey: A life without biosimilars (S Scowcroft)</li> <li>• Why we need biosimilars: Mapping out a path to sustainable care (P Cornes)</li> <li>• A patient's journey: A life with biosimilars (S Scowcroft)</li> <li>• Panel speaks: Navigating the totality of evidence for rituximab biosimilars: how much and which data are necessary? (AG Vulto)</li> <li>• A patient's journey: Does extrapolation matter? (S Scowcroft)</li> <li>• Panel speaks: Driving data extrapolation in hematologic malignancies: Key considerations for clinical practice (C Buske)</li> <li>• Ask the faculty and closing remarks (P Cornes)</li> </ul>	
<b>June 17<sup>th</sup> (Sunday)</b>		
9.30 – 11.00	<p><b>Education Session:</b> Chronic myeloid leukemia</p> <p>Chair: Prof. S. Sauße (Universitätsklinikum Mannheim, Germany)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• Single cell genomics in CML (A Mead)</li> <li>• Immune targeting of CML to improve treatment outcome (A Burchert)</li> <li>• TFR treatment goal for all CML patients (D Rea)</li> </ul>	Room K1

Time slots	Sessions	Location
11.15 – 12.45	<b>Education Session:</b> Chronic myeloid leukemia Chair: Prof. S. Saußeke (Universitätsklinikum Mannheim, Germany) Program: <ul style="list-style-type: none"> <li>• Single cell genomics in CML (A Mead)</li> <li>• Immune targeting of CML to improve treatment outcome (A Burchert)</li> <li>• TFR treatment goal for all CML patients (D Rea)</li> </ul>	Room K1